Unser klinisches Studienprogramm in der Schweiz

Wir führen klinische Studien in verschiedenen Krebsarten durch, welche die klinische Forschung vorantreiben und schliesslich die Patientenversorgung und Behandlungsergebnisse verbessern sollen.

Wir engagieren uns für lokale klinische Forschung und innovative Wissenschaft

Aktuell werden in der Schweiz 28 Studien mit Medikamenten von AstraZeneca durchgeführt, unter anderem zu Lungen-, Brust-, Eierstock-, Kopf- und Halskrebs sowie soliden Tumoren (Stand: 06/2021).


Überblick über unsere laufenden klinischen Studien in der Schweiz (Stand: 06/2021)

Lungenkrebs

D5160C00007 - FLAURA – active, recruitment closed

A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Study Sites: Lucerne, Winterthur, Zurich

 

D419AC00001 – MYSTIC – active, recruitment closed

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC).
Study Sites: Bellinzona, Lausanne

 

D5160C00022 – Astris – completed

Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI).
Study Sites: Bellinzona, Berne, Lucerne, St. Gallen

 

D910LC00001 – MeRmaiD-1 – active, enrolling

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (Mermaid-1).
Study Sites: Lausanne, Zurich

 

D910MC00001 – MeRmaiD-2 –  in start up

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.
Study sites: Lausanne, Zurich

 

D516AC00001 – NeoADAURA –  active

A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
Study Site: Zurich

 

D9108C00002 – NeoCOAST – active

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)
Study Site: Zurich

 

Brustkrebs

D0819C00003 - OlympiAD – active, recruitment closed

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Study sites: Berne, Lausanne, Zurich

 

D081CC00006 – OlympiA – active, recruitment closed

A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Study Sites: Berne, Lausanne, Zurich

 

DS8201-A-U303 - Destiny Breast-04 – active, recruitment closed

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Study Sites: Aarau, Basel, Chur, Lausanne, St. Gallen, Winterthur, Zurich

 

D9673C00007 – Destiny Breast12 – not yet active

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Study sites: tba

 

D8532C00001 – SERENA4 – not yet active

A Randomised, Multicentre, Double-Blind, Phase 3 Study of AZD9833 (An Oral SERD) plus Palbociclib plus Anastrozole Placebo versus Anastrozole plus Palbociclib plus AZD9833 Placebo for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.
Study sites: Basel, Berne, Zurich

 

Eierstockkrebs

D0816C00020 – OPINION – active, recruitmend closed

A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy.
Study Sites: Basel, Bellinzona, Frauenfeld, Geneva, Zurich

 

Kopf- und Halskrebs

D7310C00001 – Interlink-1 – active

A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.
Study Sites: Basel, Berne, Lausanne

 

Solide Tumore

D0810L00001 – recruitment closed

A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors.
Study Site: Bellinzona, Chur

 

D081KC00001 – MEDIOLA – recruitment closed

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors.
Study Sites: Chur, Lausanne

 

Extern gesponserte klinische Studien

Darüber hinaus unterstützt AstraZeneca 12 extern gesponserte, von Wissenschaftlern/Prüfärzten initiierte Studien (externally sponsored research/investigator initiated trials, ESRs/IITs). Sechs dieser Studien werden von der Schweizerischen Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) durchgeführt, drei weitere laufen international mit der European Thoracic Oncology Platform (ETOP), eine mit der International Breast Cancer Study Group (IBCSG) und eine mit der International Extranodal Lymphoma Study Group (IELSG). Die beträchtlichen Investitionen in diese lokal durchgeführten Studien verdeutlichen unser Engagement zur Unterstützung der starken klinischen Forschungsgemeinschaft in der Schweiz, um Behandlungsdefizite zu beseitigen und die klinische Forschung voranzutreiben, damit letztendlich die PatientInnenversorgung verbessert und günstigere Behandlungsergebnisse erzielt werden können.


Eine Übersicht über alle Studien in der Schweiz, für die Teilnehmer gesucht werden, finden Sie hier: www.kofam.ch

CH-4301; 06/2021